Pharma BD Deal Intelligence
BioSpace framed the deal as Horizon executing on rare-disease M&A momentum, picking up a revenue-boosting commercial pipeline anchored by Ravicti.
Horizon to acquire Hyperion for $46.00 per share, about $1.1 billion in cash, adding RAVICTI and BUPHENYL; expected immediately accretive to adjusted EPS and…
Analysts were positive on Horizon's decision to acquire Hyperion, noting the deal diversifies the portfolio and significantly boosts both top line and bottom…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Horizon Pharma acquired Hyperion Therapeutics for $46/share or approximately $1.1B in cash, adding Ravicti and Buphenyl for urea cycle disorders to Horizon's rare disease portfolio.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Horizon Pharma plc / Hyperion Therapeutics, Inc. (this deal) | 2015 | $1.1B | 79 |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
| Horizon Pharma plc / Raptor Pharmaceutical Corp. | 2016 | $860M | 46 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| AstraZeneca PLC / Amolyt Pharma | 2024 | $1.1B | 73 |
| Sanofi SA / Inhibrx Inc. | 2024 | $2.2B | 70 |
← Browse all deals · How we score deals
More: 2015 deals · Horizon Pharma plc deals · Rare Disease deals